Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
April 13, 2022 04:00 ET
|
Highlight Therapeutics
BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD-1 treatment Primary endpoint met with a 30%...
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 15, 2022 06:20 ET
|
Highlight Therapeutics
MADRID, Spain, March 15, 2022 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced an...
Highlight Therapeutics: BO-112 published in JITC
December 02, 2021 04:04 ET
|
Highlight Therapeutics
Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of BO-112 +...
Positive Phase-IIb-Ergebnisse bei Zweitlinienbehandlung von Melanomen
November 13, 2021 15:52 ET
|
Highlight Therapeutics
Highlight Therapeutics gibt auf der SITC positive vorläufige Ergebnisse der Phase-IIb-Studie zu BO-112 + Anti-PD1 bei Melanompatienten mit bestätigter Progression nach Anti-PD-1-Erstlinienbehandlung...
Résultats positifs de la phase 2b pour le mélanome en 2e ligne
November 13, 2021 15:52 ET
|
Highlight Therapeutics
Highlight Therapeutics annonce les résultats préliminaires positifs de l'étude de phase 2b sur le BO-112 + anti-PD1 chez des patients atteints de mélanome dont la maladie avait progressé avec...
Positive Phase 2b results in 2nd line melanoma
November 12, 2021 11:37 ET
|
Highlight Therapeutics
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC Breakthrough cancer treatment shows...
Positive Phase 2b results in 2nd line melanoma
November 12, 2021 07:00 ET
|
Highlight Therapeutics
BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD1 treatment Primary endpoint met with a...
Highlight to present Phase 2 data at AACR
April 14, 2021 04:00 ET
|
Highlight Therapeutics
Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 2021 MADRID, Spain, April 14, 2021 (GLOBE NEWSWIRE) --...
Highlight & Pivotal start Phase IIa melanoma trial
March 02, 2021 06:55 ET
|
Highlight Therapeutics
Highlight Therapeutics and Pivotal work together on Melanoma therapy andlaunch a Phase IIa trial to examine BO-112 efficacy and safety Trial will examine administration of Highlight's BO-112 in...
Highlight Therapeutics Announces Second Phase II Oncology Collaboration with Merck
September 02, 2020 04:00 ET
|
Highlight Therapeutics
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA® New research studies may...